abstract
eight
differentc
ompound
nucleosid
analogu
could
present
consid
potenti
drug
candid
treatment
ebola
viru
ebov
andoro
ther
hemorrhag
fever
viru
hfv
infectionst
hey
consid
either
adenin
analogu
galidesivir
g
andr
emdesivir
ii
guanin
analogu
contain
carboxamid
entiti
ribavirin
eicar
pyrazofurin
favipiravir
eight
owe
mechan
action
hydrogen
bondedb
ase
pair
either
uracil
ii
cytosin
four
eight
compound
galidesivir
remdesivir
pyrazofurin
cnucleosid
nd
two
remdesivir
also
contain
ap
hosphoramid
part
cnucleosid
phosphoramid
adenin
analogu
group
well
may
consid
essenti
attribut
antivir
activ
hemorrhag
fever
viru
hfv
infect
includ
lassa
ebola
highlight
potenti
target
antivir
agent
essenti
remain
unchang
nd
later
w
ear
still
await
first
antivir
drug
ob
ef
ormal
approv
treatment
hfv
infectionst
first
antivir
compound
ever
report
effect
treatment
hfv
infect
lassa
could
use
point
ill
well
postexposur
prophylaxi
ribavirin
ribavirin
virazol
figur
first
synthet
nucleosid
analogu
ever
report
activ
ab
road
spectrumo
fb
oth
rna
dna
virus
final
remark
sidwel
et
al
state
right
antivir
spectrum
virazol
broadest
ever
report
syntheticm
ateri
induc
interferon
although
eventu
clinicalu
se
virazol
would
eventu
limit
rna
viru
infect
one
structur
analogu
mention
latter
articl
wase
icar
eicar
origin
report
antileukem
agent
mice
antivir
activ
ts
how
imilar
spectrum
ribavirin
activ
pox
toga
arena
reo
orthomyxoand
paramyxoviru
infect
ap
otenc
greater
ribavirin
origin
ascertain
ribavirin
eicar
also
provedt
ob
eapot
inhibitor
imp
dehydrogenas
thu
block
biosynthesi
gmp
deplet
intracellular
gtp
dgtp
pool
result
decreas
biosynthesi
gmp
ay
also
explain
variouso
ther
effect
eicar
potenti
effect
antihiv
activ
ddi
inhibitori
effect
replic
av
arieti
virus
doublestrand
rna
viru
ipnv
infecti
pancreat
necrosi
viru
latter
public
yet
anoth
antiviralc
ompound
pyrazofurin
mention
pecif
inhibitor
ipnv
pyrazofurin
bdribofuranosyl
figur
inhibitor
omp
decarboxylas
key
enzym
de
novo
pyrimidin
mononucleotid
biosynthesi
th
provent
ob
ea
ctivea
gainst
rna
virus
picorna
polio
coxsackieb
toga
sindbi
flavi
yellow
fever
rna
virus
paramyxo
measl
rsv
orthomyxo
influenza
rhabdo
vsv
arena
junin
tacarib
pyrazofurinh
found
exquisit
potent
inhibitor
vsv
vesicular
stomat
viru
belong
af
amili
rhabdovirida
close
relatedt
ot
famili
filovirida
ebola
viru
ebov
marburg
viru
belong
vsv
handl
convent
afeti
condit
wherea
ebov
marburgv
iru
requir
biosafeti
level
vsv
could
therefor
recommend
ap
aradigm
predict
antivir
activ
ebov
pyrazofurinh
far
evalu
potentiala
ctiviti
ebov
done
alreadi
done
neplanocin
aa
nalogu
analogu
knownt
ob
et
arget
sadenosylhomocystein
hydrolas
prototyp
class
compound
figur
two
decad
ago
aw
shownt
ob
ee
ffectiv
al
ethal
ebov
infect
mice
compound
induc
massiv
increas
interferona
product
ebovinfect
mice
tartl
observ
never
follow
review
possibl
therapeut
trategiest
block
ebov
infect
im
ention
besid
andt
favipiravir
later
ad
list
remdesivir
zmapp
respons
zmapp
ixtur
three
monoclon
antibodi
direct
surfaceg
lycoprotein
ebov
w
benefici
meet
prespecifi
statist
threshold
efficaci
death
occur
patient
receiv
current
standardo
fc
alon
compar
atient
receiv
current
standard
care
plu
zmapp
appar
outbreak
ebola
end
incontrovert
evidenceo
fa
ny
intervent
could
assess
review
iw
ill
focu
potentialo
ff
avipiravir
galidesivir
remdesivir
treatment
ebov
hfv
infect
iminocnucleosid
galidesivir
w
first
report
warren
tal
activea
gainst
aw
ide
rang
virus
includ
filo
toga
bunya
arena
paramyxo
corona
flavi
orthomyxoandp
icornavirus
found
complet
protectc
ynomolgu
macaqu
marburg
viru
infect
administ
late
hour
infect
effect
block
yellow
fever
viru
infect
ah
amster
model
develop
treatmento
f
ebov
infect
galidesivir
figur
also
found
effect
zika
viru
cell
cultur
lethal
mousem
odel
antivirala
ctiviti
also
report
west
nile
viru
ypical
mosquitotransmit
flaviviru
tickbornef
lavivirus
kyasanur
forest
diseas
viru
kfdv
inhibit
infect
rift
valley
fever
viru
rvfv
osquitoborn
pathogen
caus
sever
diseas
humansa
nd
livestock
subsaharan
africa
arabian
peninsula
syrian
golden
hamster
phosphoramidatep
rodrug
pyrrolo
denin
cnucleosid
remdesivir
figur
first
report
protect
fe
bovinfect
rhesu
monkey
al
ethal
ebov
infect
wasa
lso
found
activ
emerg
virus
respiratori
syncyti
viru
rsv
hepat
cv
iru
hcv
nd
presenc
group
remdesivir
wasf
ound
critic
provid
select
toward
viral
rna
polymeras
found
highli
inhibitori
variou
virus
filo
pneumo
paramyxoand
coronavirus
inhibit
epidem
zoonot
coronavirus
might
prove
effect
emerg
coronavirus
futur
emphas
sheahan
tal
viral
rna
polymeras
proofread
exoribonucleas
suggest
respons
fort
coronaviru
suscept
remdesivir
viral
rna
polymeras
also
identifi
target
nzyme
paramyxovirus
ie
nipah
viru
antivir
activ
ebov
rnadependentr
na
polymeras
rdrp
rsv
rdrp
chain
termin
delayeda
nd
predominantli
seen
posit
first
newborn
babi
surviv
congenit
ebov
infect
receiv
remdesivir
addit
zmapp
ab
uffi
coat
transfus
ebola
survivor
favipiravir
figur
ap
yrazin
deriv
share
ac
ommon
structur
featur
ac
arboxamid
entiti
w
ith
ribavirin
eicar
pyrazofurin
andw
hich
also
essenti
hydrogen
bond
part
guanin
hn
c
alreadi
mention
ribavirin
eicar
would
primarili
owe
antivir
activ
interfer
imp
dehydrogenas
ak
ey
enzym
biosynthesi
gmp
gtpi
et
eriksson
et
al
report
inhibit
influenzav
iru
rna
polymeras
ribavirint
riphosph
nd
furuta
et
al
reveal
vitro
vivo
activ
influenza
viru
attribut
mode
action
pecif
inhibit
influenzaviru
rna
polymeras
rtp
ribofuranosyl
triphosph
end
scheme
first
convert
ribofuranosyl
monophosph
rmp
phosphoribosylt
ransferas
process
kinas
diphosph
rdp
triphosph
rtp
latter
would
interact
ag
tpcompetit
manner
viral
rna
synthesi
favipiravir
av
iral
rna
polymeras
inhibitor
offer
great
potenti
treatment
aw
idev
arieti
rna
viru
infect
review
repeatedli
sidwel
et
al
demonstr
inhibit
al
ethal
avian
influenza
v
iru
infectioni
nm
ice
confirm
kiso
et
al
ascertainedt
hat
influenzaa
virusinfect
cell
metabol
rtp
latter
incorpor
nascent
rna
strand
ap
urin
nucleotid
analog
reminisc
gmp
inhibit
strand
extens
rtp
act
ag
tpcompetit
inhibitor
influenza
viral
rna
polymeras
favipiravir
inhibit
vitro
replic
aw
ide
rang
influenzav
irus
includ
resistantt
oc
urrent
avail
drug
andt
hose
isol
patient
previous
receiv
favipiravir
favipiravir
approv
avigan
japan
treatment
influenza
lethal
mutagenesi
hasb
een
propos
ak
ey
mechan
activ
favipiravir
againsti
nfluenzaa
v
irus
vitro
lethalm
utagenesi
also
suggest
activ
favipiravir
noroviru
replic
hepat
cv
iru
mechan
antivir
activ
origin
propos
ribavirin
howev
activ
ribavirin
yellow
fever
viru
could
explain
errorpron
mechan
favipiravir
proven
ffectiv
againstv
irtual
hemorrhag
fever
viru
infect
renaand
bunyavirida
pichind
viru
arenaviru
lassa
fever
viru
yellow
fever
viru
western
equin
enceph
viru
west
nile
viru
punta
ro
ap
hleboviru
hantaviru
mapor
rift
valley
fever
viru
phleboviru
bunyavirida
crimeancongo
hemorrhag
fever
viru
nairoviru
bunyavirida
severef
ever
thrombocytopenia
syndrom
viru
sftsv
ar
ecent
identifi
emerg
viru
noroviru
calicivirida
resist
never
report
except
chikungunya
viru
alphavirida
acquir
resist
due
mutat
rnadependentr
na
polymeras
rdrp
favipiravir
prove
uccess
treatment
ebov
infect
mice
nonhuman
primat
treat
intraven
favipiravir
f
ive
six
anim
surviv
al
ethal
marburg
viru
infect
patient
ebov
infect
wwwchemasianjorg
sierra
leon
favipiravir
found
increas
surviv
rate
anoth
studi
carri
guinea
end
statement
favipiravir
monotherapi
merit
further
tudi
patient
mediumt
oh
igh
viremia
high
viremia
guedj
et
al
conclud
favipiravir
mayh
ave
ap
otentialr
ole
high
dose
treatment
ebov
infect
human
ta
king
account
rhabdoand
filovirus
close
relat
ti
sn
ot
surpris
favipiravir
also
advoc
postexposur
prophylaxi
rabiesviru
ap
otenti
altern
rabi
immunoglobulin
compound
describ
consid
either
adenin
deriv
galidesivir
r
emdesivir
guanin
deriv
ribavirin
eicar
pyrazofurin
f
avipiravir
immediatelyo
bviou
adenin
deriv
expect
interferew
ith
viral
rna
synthesi
level
rdrp
rnadependentr
na
polymeras
serv
competit
inhibitor
respectt
atp
base
hydrogen
bond
form
adenin
uracil
figur
addit
adenin
analogu
also
serv
sadenosylhomocystein
sah
hydrolas
inhibitor
thu
interf
sadenosylmethionin
sam
dependentmethylationr
eaction
ribavirin
eicar
pyrazofurin
favipiravir
would
abl
act
guanin
eriv
thu
compet
gtp
rdrp
level
less
obviou
yet
ompound
share
carboxamid
group
reminisc
carboxamid
c
h
part
guanin
could
explain
hydrogen
bondingw
ith
cytosin
figur
addit
action
rdrp
level
carboxamidecontain
deriv
could
also
interfer
imp
dehydrogenas
activ
hu
suppress
biosynthesi
gtp
sh
specif
demonstr
ribavirin
eicar
exact
mechan
action
favipiravir
remain
assess
tm
ay
well
vari
one
viru
anothera
sf
ar
activ
favipiravir
rtp
influenzaaviru
polymeras
concern
ascrib
ambigu
basepair
ip
ropos
cnucleosidess
hould
revisit
propos
prompt
advent
two
new
cnucleosid
figur
meantim
pursu
galidesivir
treatment
ebov
infect
see
supra
compound
contain
group
impart
specif
activ
hepat
cv
iru
gcv
figur
also
contain
cyano
group
later
found
critic
provid
select
towardv
iral
rna
polymeras
report
potentiala
sa
na
ntihcv
agent
thoroughli
explor
potenti
activ
ebov
hemorrhag
fever
viru
hfv
infect
accord
literatur
ata
would
weaka
ctiviti
ebov
remdesivir
present
aleadingd
rug
candid
treatment
ebov
infect
chemic
attribut
ac
nucleosid
extendedb
yaphosphoramid
equippedw
ith
ac
ng
roup
galidesivir
also
acnucleosid
would
happeni
fi
tw
ould
also
contain
cn
group
would
convert
ap
hosphoramid
prodrug
f
favipiravir
ts
nnucleosid
effect
free
yellow
fever
viru
infect
hamster
less
punta
ro
viru
mice
would
happen
would
convertedt
cnucleosid
furthermor
extend
ap
hosphora
wwwchemasianjorg
wileyvch
verlag
gmbh
co
kgaa
weinheim
midat
entiti
lso
forgotten
cnucleosid
pyrazofurin
could
convert
phosphoramid
eicar
containsa
ne
thynyl
reminisc
cyano
group
could
first
transform
cnucleosid
convert
phosphoramid
scheme
chemic
intervent
may
provid
potenti
clue
design
new
medicin
ebovand
hfv
infect
candid
antivir
compoundsc
urrent
availablef
treatment
ebov
hfv
infect
galidesivir
g
remdesivir
r
ibavirin
eicar
pyrazofurin
andf
avipiravirthey
box
attempt
increas
efficaci
potenti
lower
toxic
could
applic
first
convert
cnucleosid
subsequ
ot
heir
phosphoramid
scheme
remdesivir
w
hich
na
ddition
also
contain
ac
yanogroup
manipul
alreadi
achiev
authordeclar
conflict
interest
keyword
antivir
ebola
hemorrhag
fever
virus
nucleosid
analogu
